个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Zhou Jian[1] * ; Sun Huichuan[1] * ; Wang Zheng[1] * ; Cong Wenming[2] ; Zeng Mengsu[3] ; Zhou Weiping[4] ; Bie Ping[5] ; Liu Lianxin[6] ; Wen Tianfu[7] ; Kuang Ming[8] ; Han Guohong[9] ; Yan Zhiping[10] ; Wang Maoqiang[11] ; Liu Ruibao[12] ; Lu Ligong[13] ; Ren Zhenggang[1] ; Zeng Zhaochong[14] ; Liang Ping[15] ; Liang Changhong[16] ; Chen Min[17] ; Yan Fuhua[18] ; Wang Wenping[19] ; Hou Jinlin[20] ; Ji Yuan[21] ; Yun Jingping[22] ; Bai Xueli[23] ; Cai Dingfang[24] ; Chen Weixia[25] ; Chen Yongjun[26] ; Cheng Wenwu[27] ; Cheng Shuqun[4] ; Dai Chaoliu[28] ; Guo Wengzhi[29] ; Guo Yabing[30] ; Hua Baojin[31] ; Huang Xiaowu[1] ; Jia Weidong[32] ; Li Qiu[33] ; Li Tao[34] ; Li Xun[35] ; Li Yaming[36] ; Li Yexiong[37] ; Liang Jun[38] ; Ling Changquan[39] ; Liu Tianshu[40] ; Liu Xiufeng[41] ; Lu Shichun[42] ; Lv Guoyue[43] ; Mao Yilei[44] ; Meng Zhiqiang[45] ; Peng Tao[46] ; Ren Weixin[47] ; Shi Hongcheng[48] ; Shi Guoming[1] ; Shi Ming[8] ; Song Tianqiang[49] ; Tao Kaishan[50] ; Wang Jianhua[10] ; Wang Kui[4] ; Wang Lu[51] ; Wang Wentao[7] ; Wang Xiaoying[1] ; Wang Zhiming[52] ; Xiang Bangde[53] ; Xing Baocai[54] ; Xu Jianming[55] ; Yang Jiamei[4] ; Yang Jianyong[56] ; Yang Yefa[57] ; Yang Yunke[24] ; Ye Shenglong[1] ; Yin Zhenyu[58] ; Zeng Yong[7] ; Zhang Bixiang[59] ; Zhang Boheng[1] ; Zhang Leida[60] ; Zhang Shuijun[61] ; Zhang Ti[51] ; Zhang Yanqiao[62] ; Zhao Ming[63] ; Zhao Yongfu[61] ; Zheng Honggang[64] ; Zhou Ledu[65] ; Zhu Jiye[66] ; Zhu Kangshun[67] ; Liu Rong[10] ; Shi Yinghong[1] ; Xiao Yongsheng[1] ; Zhang Lan[1] ; Yang Chun[3] ; Wu Zhifeng[14] ; Dai Zhi[1] ; Chen Minshan[8] ; Cai Jianqiang[68] ; Wang Weilin[69] ; Cai Xiujun[23] ; Li Qiang[49] ; Shen Feng[4] ; Qin Shukui[41] ; Teng Gaojun[70] ; Dong Jiahong[71] ; Fan Jia[1] ;
机构： [1]Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. [2]Department of Pathology, The Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. [3]Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. [4]The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. [5]Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China. [6]Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China. [7]Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China. [8]Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. [9]Department of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China. [10]Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. [11]Department of Interventional Radiology, Chinese PLA General Hospital, Beijing, China. [12]Department of Interventional Radiology, The Tumor Hospital of Harbin Medical University, Harbin, China. [13]Department of Interventional Oncology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. [14]Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. [15]Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China. [16]Department of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. [17]Editorial Department of Chinese Journal of Digestive Surgery, Chongqing, China. [18]Department of Radiology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China. [19]Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China. [20]Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China. [21]Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China. [22]Department of Pathology, Tumor Prevention and Treatment Center, Sun Yat-sen University, Guangzhou, China. [23]Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. [24]Department of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. [25]Department of Radiology, West China Hospital of Sichuan University, Chengdu, China. [26]Department of Hematology, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [27]Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China. [28]Department of Hepatobiliary and Spleenary Surgery, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China. [29]Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. [30]Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China. [31]Graduate School, Beijing University of Chinese Medicine, Beijing, China. [32]Department of Hepatic Surgery, Affiliated Provincial Hospital, Anhui Medical University, Hefei, China. [33]Department of Oncology, West China Hospital, Sichuan University, Chengdu, China. [34]Department of General Surgery, Qilu Hospital, Shandong University, Jinan, China. [35]The First Hospital of Lanzhou University, Lanzhou, China. [36]Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, China. [37]Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [38]Department of Oncology, Peking University International Hospital, Beijing, China. [39]Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai, China. [40]Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China. [41]Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China. [42]Institute and Hospital of Hepatobiliary Surgery of Chinese PLA, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, China. [43]Department of General Surgery, The First Hospital of Jilin University, Jilin, China. [44]Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China. [45]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. [46]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. [47]Department of Interventional Radiology the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. [48]Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. [49]Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. [50]Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China. [51]Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China. [52]Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China. [53]Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China. [54]Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing, China. [55]Department of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China. [56]Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. [57]Department of Hepatic Surgery and Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. [58]Department of Hepatobiliary Surgery, Zhongshan Hospital of Xiamen University, Xiamen, China. [59]Department of Surgery, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [60]Department of Hepatobiliary Surgery Institute, Southwest Hospital, Third Military Medical University, Chongqing, China. [61]Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, ZhengZhou, China. [62]Department of Gastrointestinal Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China. [63]Minimally Invasive Interventional Division, Liver Cancer Group, Sun Yat-Sen University Cancer Center, Guangzhou, China. [64]Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. [65]Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China. [66]Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China. [67]Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. [68]Department of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [69]Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. [70]Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China. [71]Department of Hepatobiliary and Pancreas Surgery, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China.
出处：
DOI： 10.1159/000530495
ISSN：

关键词： Primary liver cancer Hepatocellular carcinoma Guidelines China Diagnosis Treatment

摘要：
Primary liver cancer, of which around 75-85% is hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people.Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China in June 2017, which were updated by the National Health Commission in December 2019, additional high-quality evidence has emerged from researchers worldwide regarding the diagnosis, staging, and treatment of liver cancer, that requires the guidelines to be updated again. The new edition (2022 Edition) was written by more than 100 experts in the field of liver cancer in China, which not only reflects the real-world situation in China but also may reshape the nationwide diagnosis and treatment of liver cancer.The new guideline aims to encourage the implementation of evidence-based practice and improve the national average 5-year survival rate for patients with liver cancer, as proposed in the "Health China 2030 Blueprint."© 2023 The Author(s). Published by S. Karger AG, Basel.

语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 1 区 医学
小类 | 1 区 胃肠肝病学 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 胃肠肝病学 1 区 肿瘤学
第一作者：
第一作者机构： [1]Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhou Jian,Sun Huichuan,Wang Zheng,et al.Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)[J].Liver Cancer.2023,12(5):405-444.doi:10.1159/000530495.
APA：
Zhou Jian,Sun Huichuan,Wang Zheng,Cong Wenming,Zeng Mengsu...&Fan Jia.(2023).Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).Liver Cancer,12,(5)
MLA：
Zhou Jian,et al."Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)".Liver Cancer 12..5(2023):405-444

相关文献

[1]Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition) [2]Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition) [3]肝癌AASLD、EASL、JSH指南及中国诊疗规范的比较 [4]Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition) [5]The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017. [6]Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer [7]The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines from 2001 to 2017. [8]Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition [9]Quality assessment of clinical practice guidelines on the treatment of hepatocellular carcinoma or metastatic liver cancer. [10]The characteristics of breast cancer subtypes: implications for treatment guidelines and individualized treatment strategies in China.

资源点击量：52808 今日访问量：1 总访问量：4560 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号